Stereotaxis (NYSE: STXS) will be added to the Russell 2000 and Russell 3000 indexes after the close on June 26, as part of the Russell indexes annual reconstitution.
“This is another step forward in our effort to improve awareness of our differentiated technology, clinical value and growth opportunity,” David Fischel, chairman and CEO of Stereotaxis, said in a statement.
The Russell 3000 index measures the performance of the largest 3,000 publicly-traded companies in the U.S., while the Russell 2000 index is the most common benchmark for small capitalization companies.
